摘要:
The present invention relates to a Cynara scolymus extract with a high content of caffeoylquinic acids, and a composition containing said Cynara scolymus extract with a Phaseolus vulgaris extract. Said composition is useful in reducing obesity as it reduces cholesterol, triglycerides and blood glucose by sensitizing the cells to insulin. This combination, when taken before meals, reduces the appetite, leading to a reduction in body weight. The extracts are preferably formulated in Oenothera biennis oil, fish oil, or oils rich in unsaturated ω-3 fatty acids.
摘要:
The present invention relates to a Cynara scolymus extract with a high content of caffeoylquinic acids, and a composition containing said Cynara scolymus extract with a Phaseolus vulgaris extract.Said composition is useful in reducing obesity as it reduces cholesterol, triglycerides and blood glucose by sensitising the cells to insulin. This combination, when taken before meals, reduces the appetite, leading to a reduction in body weight. The extracts are preferably formulated in Oenothera biennis oil, fish oil, or oils rich in unsaturated ω-3 fatty acids.
摘要:
The present invention relates to a Cynara scolymus extract with a high caffeoylquinic acid content, obtainable by extraction from undried globe artichoke heads with alcohols having up to three carbon atoms.
摘要:
The present invention relates to a Cynara scolymus extract with a high content of caffeoylquinic acids, and a composition containing said Cynara scolymus extract with a Phaseolus vulgaris extract.Said composition is useful in reducing obesity as it reduces cholesterol, triglycerides and blood glucose by sensitising the cells to insulin. This combination, when taken before meals, reduces the appetite, leading to a reduction in body weight. The extracts are preferably formulated in Oenothera biennis oil, fish oil, or oils rich in unsaturated ω-3 fatty acids.
摘要:
This invention relates to the combination of α-amylase inhibitors prepared from Phaseolus vulgaris with α-glucosidase inhibitors obtained from Salacia oblonga and other species. The α-amylase inhibitor is accompanied by a quantity of lectins that reduces the amount of glucose originating from the starches present in the diet, and considerably reduces the appetite after repeated administration. The combination with α-glucosidase inhibitors, such as extracts of Salacia or the thiosugars present in it, further reduce the blood glucose, acting synergically, and consequently reduce the synthesis of fats from carbohydrates.
摘要:
This invention relates to the combination of α-amylase inhibitors prepared from Phaseolus vulgaris with α-glucosidase inhibitors obtained from Salacia oblonga and other species. The α-amylase inhibitor is accompanied by a quantity of lectins that reduces the amount of glucose originating from the starches present in the diet, and considerably reduces the appetite after repeated administration. The combination with α-glucosidase inhibitors, such as extracts of Salacia or the thiosugars present in it, further reduce the blood glucose, acting synergically, and consequently reduce the synthesis of fats from carbohydrates.
摘要:
The present invention relates to the microbial biotransformation of colchiconic compounds into derivative compounds, which are glycosylated exclusively at the C-3 position of the six-member ring. The process of the present invention provides the 3-O-glycosyl derivatives in high yields and purity.
摘要:
The invention relates to hydroxyproline-rich glycoproteins, which can be obtained by acid alcohol extraction from Taxus supp., Gingko biloba, Lycopersicum esculentum and Daucus carota cell cultures, having the following characteristics: average molecular weight 20,000 Daltons with variability interval 12,000 to 38,000, determined by means of gel permeation and electrophoresis; high solubility in water.
摘要:
Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an α-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.